Behind the science

'We’re innovating to help keep COPD patients out of hospital and exacerbation-free'

Most patients hospitalised with chronic obstructive pulmonary disease (COPD) are readmitted within a year and typically enter a spiral of decline. Here, Dr Kaivan Khavandi, SVP of R&D for Respiratory, Immunology and Inflammation at GSK, explains why we can’t afford to ignore these outcomes – and how his team aims to prevent them.